Privium Fund Management B.V. Acquires 5,350 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Privium Fund Management B.V. increased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 35.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,366 shares of the company’s stock after buying an additional 5,350 shares during the period. Privium Fund Management B.V.’s holdings in Dyne Therapeutics were worth $480,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. FMR LLC increased its stake in Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares during the period. RTW Investments LP grew its holdings in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after purchasing an additional 431,503 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after purchasing an additional 2,189,339 shares during the period. RA Capital Management L.P. raised its stake in Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp raised its stake in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after purchasing an additional 440,890 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DYN. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.85.

Dyne Therapeutics Trading Up 2.2 %

NASDAQ DYN opened at $12.58 on Wednesday. Dyne Therapeutics, Inc. has a 12 month low of $11.18 and a 12 month high of $47.45. The firm has a market capitalization of $1.42 billion, a PE ratio of -3.53 and a beta of 1.11. The business’s 50-day moving average price is $14.10 and its two-hundred day moving average price is $24.66.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 6,237 shares of company stock worth $77,760 over the last three months. 20.77% of the stock is owned by company insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.